Interesting facts
Interesting Facts about 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic Acid
This intriguing compound, known scientifically as 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid, is notable for its unique structure and potential applications in various fields. Here are some fascinating insights:
- Complex Structure: The compound features a multi-ring structure that provides stability and may influence its reactivity. The pyranoindole framework is particularly significant due to its incorporation of nitrogen in a heterocyclic system.
- Potential Therapeutic Applications: Compounds like this one may have implications in medicinal chemistry, particularly in developing drugs targeting neurological or psychological disorders, owing to their indole-like structure, which is often found in many biologically active substances.
- Synthetic Interest: The synthesis of this compound could represent challenges and opportunities for chemists. Researchers may explore innovative synthetic routes that could lead to the discovery of new analogs with enhanced activity.
- Natural Product Inspiration: The design of this compound may draw inspiration from natural products known for their psychoactive properties. Understanding its mechanism of action could unveil new pathways for drug development.
As you explore this compound further, consider the broader implications of its structure and potential applications in both pharmaceutical sciences and organic chemistry. The intersection of synthetic methods and biological activity remains a thrilling area of study for advancing scientific knowledge.
Synonyms
etodolac
41340-25-4
Etodolic acid
Lodine
Ultradol
Lodine XL
Etodolaco
Edolan
Etodolacum
Ramodar
Tedolan
Zedolac
rac-Etodolac
AY-24236
AY-24,236
Eccoxolac
Flancox
Napilac
Lodin xl
AY 24236
Etodolacum [INN-Latin]
Etodolaco [INN-Spanish]
(rs)-etodolic acid
CCRIS 3923
2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-
NSC 282126
NSC-282126
CHEBI:4909
DTXSID9020615
Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-
NIH-9918
MFCD00133313
NSC282126
UNII-2M36281008
CHEMBL622
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid
(+/-)-ETODOLAC
DTXCID30615
AY-24-236
MLS000028474
Etodolac [USAN:USP:INN:BAN]
(+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid
(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
2M36281008
SMR000058443
Etodolacum (INN-Latin)
Etodolaco (INN-Spanish)
ETODOLAC (MART.)
ETODOLAC [MART.]
Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-
ETODOLAC (USP-RS)
ETODOLAC [USP-RS]
(+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
(RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
ETODOLAC (EP MONOGRAPH)
ETODOLAC [EP MONOGRAPH]
ETODOLAC (USP MONOGRAPH)
ETODOLAC [USP MONOGRAPH]
Etodolac (USAN:USP:INN:BAN)
Hypen
1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid
1,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO(3,4-B)INDOL-1-ACETIC ACID
PYRANO(3,4-B)INDOLE-1-ACETIC ACID, 1,8-DIETHYL-1,3,4,9-TETRAHYDRO-(+/-)-
SR-01000000100
Etodolsaure
Etogesic
Osteluc
etodolac o
EtodolacER
rac Etodolac
1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-ylacetic acid
Etodlic Acid
EtoGesic Tablets
(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano(3,4-b)indol-1-yl)-acetic acid
(1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-yl)acetic acid
Lodine SR
RAK-591
NCGC00016849-01
Etodolac,(S)
Prestwick_209
CAS-41340-25-4
Etodolac (Standard)
Lodine (TN)
Etodolac Assay Standard
Spectrum_001244
ETODOLAC [USAN]
ETODOLAC [INN]
ETODOLAC [JAN]
ETODOLAC [MI]
ETODOLAC [VANDF]
Opera_ID_1774
Prestwick0_000231
Prestwick1_000231
Prestwick2_000231
Prestwick3_000231
Spectrum2_001387
Spectrum3_001429
Spectrum4_000410
Spectrum5_001347
ETODOLAC [WHO-DD]
SCHEMBL3903
Lopac0_000479
BSPBio_000301
BSPBio_003138
KBioGR_000680
KBioSS_001724
Etodolac - Bio-X trade mark
MLS001077315
MLS006011566
DivK1c_000147
ETODOLAC [GREEN BOOK]
SPECTRUM1501005
Etodolac (JP18/USP/INN)
SPBio_001374
SPBio_002222
ETODOLAC [ORANGE BOOK]
BPBio1_000333
GTPL7185
Etodolac for peak identification
HMS500H09
KBio1_000147
KBio2_001724
KBio2_004292
KBio2_006860
KBio3_002358
M01AB08
NINDS_000147
HMS1568P03
HMS1921B09
HMS2092O20
HMS2095P03
HMS2231D04
HMS3259P10
HMS3261O20
HMS3374G09
HMS3712P03
Pharmakon1600-01501005
BBC19746
BCP28411
Etogesic Sterile Injectable Solution
Tox21_110644
Tox21_202218
Tox21_500479
1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid
BDBM50016799
CCG-39005
HY-76251R
NSC757821
AKOS015838610
Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-
Tox21_110644_1
AC-4231
CS-0832
DB00749
FR27516
LP00479
NC00718
NSC-757821
SDCCGSBI-0050463.P004
IDI1_000147
NCGC00015399-03
NCGC00015399-04
NCGC00015399-05
NCGC00015399-06
NCGC00015399-07
NCGC00015399-08
NCGC00015399-09
NCGC00015399-11
NCGC00015399-12
NCGC00015399-13
NCGC00015399-15
NCGC00015399-16
NCGC00015399-26
NCGC00015399-27
NCGC00089769-02
NCGC00089769-03
NCGC00089769-04
NCGC00089769-05
NCGC00089769-06
NCGC00089769-07
NCGC00259767-01
NCGC00261164-01
BR164431
HY-76251
SY057989
SBI-0050463.P003
AB00052194
E0858
EU-0100479
NS00010209
C06991
D00315
E 0516
EN300-119494
Pyrano[3, 1,8-diethyl-1,3,4,9-tetrahydro-
AB00052194_17
Q2465218
SR-01000000100-2
SR-01000000100-4
SR-01000000100-7
BRD-A74667430-001-05-3
BRD-A74667430-001-15-2
BRD-A74667430-001-23-6
1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid
Etodolac, European Pharmacopoeia (EP) Reference Standard
F2173-0681
Z1521549186
Etodolac, United States Pharmacopeia (USP) Reference Standard
1,8-Diethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid
Pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-
1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid;(+/-)-Etodolac
2-((1RS)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-yl)acetic acid
AY 24,236; AY 24236;AY-24,236; AY-24236; AY24,236; AY24236
Etodolac for peak identification, European Pharmacopoeia (EP) Reference Standard
1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid;(RS)-Etodolic acid;(+/-)-Etodolac
Solubility of 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
The solubility of 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid (C16H17NO3) can be intriguing due to its complex structure. When considering the solubility of this compound, one must take into account several factors:
A general observation is that compounds containing both hydrophobic and hydrophilic regions can exhibit variable solubility, making experimental determination crucial. It's essential to note that "like dissolves like," so exploring a variety of solvents will provide insights into the solubility behavior of this unique chemical entity. Overall, further exploration of solubility parameters under different conditions would offer a deeper understanding of its aqueous and organic phase interactions.